Law360, New York (December 01, 2011, 4:42 PM ET) -- Teva Pharmaceutical Industries Ltd. lost its bid Thursday to overturn a lower court's ruling that AstraZeneca PLC did not infringe a Teva patent through its sales of the billion-dollar cholesterol drug Crestor.
The Court of Appeals for the Federal Circuit upheld the ruling by the U.S. District Court for the Eastern District of Pennsylvania, which held that Teva’s patent for a stabilized statin formulation of rosuvastatin calcium for the treatment of dyslipidemia was invalid since AstraZeneca first produced a batch of the drug, the opinion said....
Fed. Circ. Keeps Teva Out Of Luck Over Crestor Patent
To view the full article, take a free trial now.
